Purchase this article with an account.
Jean-Francois Korobelnik, Laurent Kodjikian, Vincent Daien, Celine Faure, Ramin Tadayoni, Audrey Giocanti-Aurégan, Pascale Massin; Real-World Use of Intravitreal Aflibercept Injections in Diabetic Macular Edema: 1-Year Interim Results of APOLLON.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3651.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess visual and anatomic outcomes in patients with diabetic macular edema (DME) treated with intravitreal aflibercept injection (IAI) in clinical practice in France.
APOLLON (NCT02924311) is an ongoing, prospective, observational, 2-year study to monitor visual (primary), anatomic, and safety outcomes following IAI in treatment-naïve or previously treated patients with DME. Previous treatment was defined as any other treatment including anti-VEGF (other than IAI), laser, or steroids. Primary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to 12 months. Interim results at 12 months are presented here.
A total of 147 patients had both baseline and 12-month data available; of these, 77 were treatment-naïve and 70 were previously treated. Of those previously treated, 44 had prior treatment with ranibizumab and 41 photocoagulation laser. Baseline demographics were largely similar between groups. Patients who were treatment-naïve had a higher BCVA score at baseline. At 12 months, change in BCVA from baseline to 12 months was +6.5 Early Treatment Diabetic Retinopathy letters (total population), +7.8 letters (treatment-naïve), and +5.0 letters (previously treated). Gains of ≥10 and ≥15 letters, respectively, were achieved in 38% and 24% of patients in the total population, 46% and 30% in the treatment-naïve group, and 32% and 19% in the previously treated group. The mean number of injections was 7.6 in the overall population as well as in both subgroups based on prior treatment. The proportion of patients who received 5 initial IAIs within the first 5 months was 51.9% in the treatment-naïve group and 31.4% in the previously treated group. Mean change in CRT from baseline to 12 months was –130 µm (total population), –121 µm (treatment-naïve), and –141 µm (previously treated). No new safety signals were observed. Ocular adverse events (AEs) were reported in 54.1% of patients. The most common ocular AEs were cataract (4.4%) and diabetic retinal edema (3.1%).
This 12-month interim analysis of the APOLLON study showed that IAI was associated with functional and anatomical improvements in both treatment-naïve and previously treated patients with DME in routine clinical practice in France.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only